{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600514,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s11606-017-4178-8","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T16:40:57Z","timestamp":1505752857000},"page":"97-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials"],"prefix":"10.1007","volume":"33","author":[{"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowri","family":"Sivaramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"4178_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","volume":"105","author":"A Gin\u00e8s","year":"1993","unstructured":"Gin\u00e8s A, Escorsell A, Gin\u00e8s P, Sal\u00f3 J, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterol. 1993;105:229-36.","journal-title":"Gastroenterol."},{"key":"4178_CR2","first-page":"S77","volume":"61","author":"P Gin\u00e8s","year":"1997","unstructured":"Gin\u00e8s P, Martin PY, Niederberger M. Prognostic significance of renal dysfunction in cirrhosis. Kidney Int Suppl. 1997;61:S77-82.","journal-title":"Kidney Int Suppl."},{"key":"4178_CR3","doi-asserted-by":"publisher","unstructured":"Heidemann J, Bartels C, Berssenbr\u00fcgge C, Schmidt H, Meister T. Hepatorenal Syndrome: Outcome of response to therapy and predictors of survival. Gastroenterol Res Pract. 2015:2015. https:\/\/doi.org\/10.1155\/2015\/457613 .","DOI":"10.1155\/2015\/457613"},{"key":"4178_CR4","first-page":"1310","volume":"56","author":"F Salerno","year":"2007","unstructured":"Salerno F, Gerbes A, Gin\u00e8s P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310-8.","journal-title":"Gut."},{"key":"4178_CR5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.03.001","volume":"53","author":"European Association for the Study of the Liver","year":"2010","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397-417.","journal-title":"J Hepatol."},{"key":"4178_CR6","unstructured":"Runyon BA. Management of adult patients with ascites due to cirrhosis: Update 2012. American Association for the Study of Liver Diseases. Available at: https:\/\/www.aasld.org\/sites\/default\/files\/guideline_documents\/adultascitesenhanced.pdf (Accessed on 22 Jun 2017)."},{"key":"4178_CR7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1365-2036.2006.03086.x","volume":"24","author":"F Fabrizi","year":"2006","unstructured":"Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006;24:935-44.","journal-title":"Aliment Pharmacol Ther."},{"key":"4178_CR8","doi-asserted-by":"publisher","first-page":"CD005162","DOI":"10.1002\/14651858.CD005162.pub3","volume":"9","author":"LL Gluud","year":"2012","unstructured":"Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2012;(9):CD005162. https:\/\/doi.org\/10.1002\/14651858.CD005162.pub3 .","journal-title":"Cochrane Database Syst Rev."},{"issue":"S7","key":"4178_CR9","doi-asserted-by":"crossref","first-page":"A119","DOI":"10.1111\/j.1440-1746.2004.03659.x","volume":"19","author":"ASMKBYDSS A","year":"2004","unstructured":"ASMKBYDSS A. Prospective randomized controlled trial of concurrent triple therapy for hepatorenal syndrome. J Gastroenterol Hepatol. 2004;19(S7):A119.","journal-title":"J Gastroenterol Hepatol."},{"key":"4178_CR10","first-page":"133","volume":"7","author":"T Greco","year":"2015","unstructured":"Greco T, Biondi-Zoccai G, Saleh O, et al. The attractiveness of network meta-analysis: a comprehensive systematic and narrative review. Heart Lung Vessel. 2015;7:133-142.","journal-title":"Heart Lung Vessel."},{"key":"4178_CR11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162:777-784.","journal-title":"Ann Intern Med."},{"key":"4178_CR12","unstructured":"Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Available from www.cochrane-handbook.org (last accessed on 1 May 2017)."},{"key":"4178_CR13","doi-asserted-by":"crossref","first-page":"h4718","DOI":"10.1136\/bmj.h4718","volume":"351","author":"P Sedgwick","year":"2015","unstructured":"Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. BMJ. 2015;351:h4718.","journal-title":"BMJ"},{"key":"4178_CR14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.","journal-title":"Stat Med"},{"key":"4178_CR15","unstructured":"Thorlund K, Engstrom J, Wetterslev J, Brok J, Imberger G, Gluud C. Trial sequential analysis. Copenhagen trial unit. Available at: http:\/\/www.ctu.dk\/tools-and-links\/trial-sequential-analysis.aspx (Accessed on 22 June 2017)."},{"key":"4178_CR16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","volume":"35","author":"PC O\u2019Brien","year":"1979","unstructured":"O\u2019Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-56.","journal-title":"Biometrics."},{"key":"4178_CR17","unstructured":"Barendregt JJ, Doi SA. MetaXL user guide. Available at: http:\/\/www.epigear.com\/index_files\/MetaXL%20User%20Guide.pdf (Accessed on 21 July 2017)."},{"key":"4178_CR18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","volume":"47","author":"C Alessandria","year":"2007","unstructured":"Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007 ;47:499-505.","journal-title":"J Hepatol."},{"key":"4178_CR19","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","volume":"150","author":"TD Boyer","year":"2016","unstructured":"Boyer TD, Sanyal AJ, Wong F, REVERSE study investigators, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150:1579-1589.e2.","journal-title":"Gastroenterology"},{"key":"4178_CR20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","volume":"62","author":"M Cavallin","year":"2015","unstructured":"Cavallin M, Kamath PS, Merli M, Italian Association for the study of the liver study group on hepatorenal syndrome, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62:567-74.","journal-title":"Hepatology."},{"key":"4178_CR21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","volume":"63","author":"M Cavallin","year":"2016","unstructured":"Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology. 2016;63:983-92.","journal-title":"Hepatology."},{"key":"4178_CR22","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/liv.12179","volume":"33","author":"S Ghosh","year":"2013","unstructured":"Ghosh S, Choudhary NS, Sharma AK, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013;33:1187-93.","journal-title":"Liver Int."},{"key":"4178_CR23","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jceh.2013.02.242","volume":"13","author":"RA Indrabi","year":"2013","unstructured":"Indrabi RA, Javid G, Zargar SA, et al. Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: A randomized prospective study. J Clin Exp Hep. 2013;13:S97.","journal-title":"J Clin Exp Hep"},{"key":"4178_CR24","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","volume":"134","author":"M Mart\u00edn-Llah\u00ed","year":"2008","unstructured":"Mart\u00edn-Llah\u00ed M, P\u00e9pin MN, Guevara M, D\u00edaz F, Torre A, TAHRS Investigators, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterol. 2008;134:1352-9.","journal-title":"Gastroenterol."},{"key":"4178_CR25","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","volume":"53","author":"S Neri","year":"2008","unstructured":"Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830-5.","journal-title":"Dig Dis Sci."},{"key":"4178_CR26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","volume":"38","author":"G Pomier-Layrargues","year":"2003","unstructured":"Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 2003;38:238-43.","journal-title":"Hepatology."},{"key":"4178_CR27","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","volume":"134","author":"AJ Sanyal","year":"2008","unstructured":"Sanyal AJ, Boyer T, Garcia-Tsao G, Terlipressin Study Group, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterol. 2008;134:1360-8.","journal-title":"Gastroenterol."},{"key":"4178_CR28","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","volume":"103","author":"P Sharma","year":"2008","unstructured":"Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103:1689-97.","journal-title":"Am J Gastroenterol."},{"key":"4178_CR29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","volume":"56","author":"V Singh","year":"2012","unstructured":"Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56:1293-8.","journal-title":"J Hepatol."},{"key":"4178_CR30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","volume":"18","author":"P Solanki","year":"2003","unstructured":"Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18:152-6.","journal-title":"J Gastroenterol Hepatol."},{"key":"4178_CR31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jceh.2015.08.003","volume":"5","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Shalimar, Vishnubhatla S, et al. Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome. J Clin Exp Hepatol. 2015;5:276-85.","journal-title":"J Clin Exp Hepatol."},{"key":"4178_CR32","first-page":"764","volume":"3","author":"H Tavakkoli","year":"2012","unstructured":"Tavakkoli H, Yazdanpanah K, Mansourian M. Noradrenaline versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial. Int J Prev Med. 2012;3:764-9.","journal-title":"Int J Prev Med."},{"key":"4178_CR33","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.14309\/00000434-201210001-00418","volume":"107","author":"S Zafar","year":"2012","unstructured":"Zafar S, Haque I, Tayyab GU, Khan G, Chaudry N. Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. Am J Gasteroenterol. 2012;107:S175-S176.","journal-title":"Am J Gasteroenterol."},{"key":"4178_CR34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0749-0704(01)00003-3","volume":"18","author":"AE Briglia","year":"2002","unstructured":"Briglia AE, Anania FA. Hepatorenal syndrome. Definition, pathophysiology, and intervention. Crit Care Clin. 2002;18:345-73.","journal-title":"Crit Care Clin."},{"key":"4178_CR35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0035-1564794","volume":"32","author":"B Erly","year":"2015","unstructured":"Erly B, Carey WD, Kapoor B, McKinney JM, Tam M, Wang W. Hepatorenal syndrome: a review of pathophysiology and current treatment options. Semin Intervent Radiol. 2015;32:445-454.","journal-title":"Semin Intervent Radiol."},{"key":"4178_CR36","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.01340406","volume":"1","author":"HM Wadei","year":"2006","unstructured":"Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006;1:1066-79.","journal-title":"Clin J Am Soc Nephrol."},{"key":"4178_CR37","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/00365520310008728","volume":"39","author":"M Kiszka-Kanowitz","year":"2004","unstructured":"Kiszka-Kanowitz M, Henriksen JH, Hansen EF, Moller S, Bendtsen F. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol. 2004;39:486\u2013492.","journal-title":"Scand J Gastroenterol"},{"key":"4178_CR38","doi-asserted-by":"crossref","first-page":"e107466","DOI":"10.1371\/journal.pone.0107466","volume":"9","author":"AP Nassar Junior","year":"2014","unstructured":"Nassar Junior AP, Farias AQ, D\u2019Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9:e107466.","journal-title":"PLoS One."},{"key":"4178_CR39","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/lt.22433","volume":"17","author":"P Gin\u00e8s","year":"2011","unstructured":"Gin\u00e8s P. Hepatorenal syndrome, pharmacological therapy, and liver transplantation. Liver Transpl. 2011;17:1244-6.","journal-title":"Liver Transpl."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-017-4178-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-017-4178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-017-4178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T21:14:27Z","timestamp":1602969267000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-017-4178-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["4178"],"URL":"https:\/\/doi.org\/10.1007\/s11606-017-4178-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,18]]}}}